Merck KGaA Non-GAAP EPS of €2.32, revenue of €5.63B; raises FY2026 outlook
Merck KGaA (MKGAF) reported Q3 Non-GAAP EPS of €2.32 and revenue of €5.63B, up 5.8% Y/Y. Organic growth was 5.1%, with foreign exchange effects adding 1.5%. EBITDA pre was stable at €1.7B, with a margin of 18.5%. The company raised its FY2026 outlook.
How this was made
The 30-second read
Why it matters
The earnings beat and outlook raise expectations for the German pharma group, but modest growth suggests limited upside.
Market read
First‑hand earnings release provides fresh data for traders; impacts European pharma sector.
What to watch
Currency effects and organic growth drivers may mask underlying margin pressure.
Background
Merck KGaA reported Q3 non‑GAAP EPS of €2.32, revenue €5.63 bn, modest EBITDA growth and raised FY2026 outlook.
Market effects
Pharma sector may see modest re‑rating based on Merck KGaA's earnings beat and guidance lift.
European markets could see slight upside in healthcare indices.
Limited; primarily affects Merck KGaA and peers.
Counterpoint
If guidance is overly optimistic, the stock could face downside on future miss.
Key entities
- companyMerck KGaA
German pharmaceutical and life‑science company reporting Q3 results.
